These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38404234)

  • 1. Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS).
    Xiong X; Zhang X; Li X; Huang T
    Expert Opin Drug Saf; 2024 Nov; 23(11):1447-1452. PubMed ID: 38404234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Rong L; Xie M; Jiang M; Qiu H; Kong L
    Br J Clin Pharmacol; 2024 Aug; 90(8):1816-1826. PubMed ID: 36702463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disproportionality Analysis of Nusinersen in the Food and Drug Administration Adverse Event Reporting System: A Real-World Postmarketing Pharmacovigilance Assessment.
    Li Y; Zhang N; Jiang T; Gan L; Su H; Wu Y; Yang X; Xiang G; Ni R; Xu J; Li C; Liu Y
    Pediatr Neurol; 2024 Sep; 158():71-78. PubMed ID: 38981277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system.
    Shen J; Luo P; Xu J
    Ther Adv Drug Saf; 2024; 15():20420986241278498. PubMed ID: 39376495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS).
    Zhou J; Zhang J; Wang Q; Peng M; Qian Y; Wu F; Rao Q; DanZhen L; Yang Y; Wang S; Liu M
    Ther Adv Drug Saf; 2024; 15():20420986241284105. PubMed ID: 39381060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.
    Yin G; Song G; Xue S; Liu F
    Sci Rep; 2024 May; 14(1):11367. PubMed ID: 38762547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
    Zhang S; Wang Y; Qi Z; Tong S; Zhu D
    Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ginkgo biloba extract safety: Insights from a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.
    Yao Y; Zhao J; Li C; Chen Y; Zhang T; Dong X; Gao W; Shang Y
    J Ethnopharmacol; 2025 Jan; 337(Pt 3):119010. PubMed ID: 39476880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Data mining and safety analysis of avatrombopag: a retrospective pharmacovigilance study based on the US food and drug administration's adverse event reporting system.
    Zhu H; Wu M
    Sci Rep; 2024 May; 14(1):11262. PubMed ID: 38760419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database.
    Cui S; Li L; Liu W; Zhao B; Zhong X
    Braz J Med Biol Res; 2024; 57():e13392. PubMed ID: 39082578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System.
    Zhao D; Long X; Wang J
    Expert Opin Drug Saf; 2024 May; 23(5):599-605. PubMed ID: 38553867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety assessment of anti-B cell maturation antigen chimeric antigen receptor T cell therapy: a real-world study based on the FDA adverse event reporting system database.
    Liu W; Lin S; Zhu X; Yin L; Liu Q; Lei S; Feng B
    Front Immunol; 2024; 15():1433075. PubMed ID: 39290710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database.
    Wu J; Wu H; Chen L; Liang H; Huang G; Yang S; Chen B; Noguchi Y; Shen Y
    Expert Opin Drug Saf; 2024 Jul; 23(7):905-916. PubMed ID: 38108285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the Safety Profile of Fast-Track COVID-19 Drugs Using the FDA Adverse Event Reporting System Database: A Comparative Observational Study.
    Kim HJ; Yoon JH; Lee KH
    Pharmacoepidemiol Drug Saf; 2024 Nov; 33(11):e70043. PubMed ID: 39533148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-marketing safety of tralokinumab: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
    Yang Z; Tang K; Chen J
    Expert Opin Drug Saf; 2024 Nov; 23(11):1439-1446. PubMed ID: 39325652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
    Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
    Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.
    Li Y; Sun S; Wu H; Zhao L; Peng W
    BMC Pharmacol Toxicol; 2024 Sep; 25(1):71. PubMed ID: 39334280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab.
    Yun X; Zhou Y; Wu D; Liu Y; Wu Q
    Expert Opin Drug Saf; 2024 May; 23(5):581-591. PubMed ID: 38600747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database.
    Yu M; Zhou L; Cao M; Ji C; Zheng Y
    Front Immunol; 2024; 15():1397692. PubMed ID: 39234238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.